Evidence map›Paper›PMID 40900261›Full record

ReviewInternational urology and nephrology2026

Precision nanotherapeutics for kidney disease: targeting inflammation and maladaptive repair.

Peng Yao, Ying Zheng, Cuicui Li

Abstract readReview
In one paragraph

Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Nanoparticles in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Peng Yao *Department of Nephrology, The Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, 610051, China. mryaopeng@163.com.
Ying Zheng *Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Cuicui LiPhysical Examination Center, Outpatient Department, The General Hospital of Western Theater Command, Chengdu, China.

Funding

Health Commission of Sichuan Province Medical Science and Technology Program 24WXXT09the Open Project of Key Laboratory of Nuclear and Radiation Damage Mechanisms and Treatment Technologies at Chengdu Medical College of Sichuan Province, The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital 2024ZDSYS09the Sichuan Science and Technology Program 2023JDRC0089
6 · The paper itself

Abstract

The kidney exhibits a remarkable capacity for repair following acute injury; however, unchecked or persistent inflammation often drives maladaptive repair, fibrosis, and progression to chronic kidney disease (CKD). Inflammation is pivotal in this process, characterized by complex, bidirectional cross talk between diverse immune cell populations and resident renal intrinsic cells. This intricate interplay critically dictates the balance between successful regeneration and pathological scarring. This review delves into the fundamental immunologic mechanisms underpinning kidney injury and maladaptive repair, analyzing the specific roles of key immune and intrinsic renal cell types, their complex communication networks, and critical signaling pathways. Recognizing the limitations of conventional systemic therapies, we extensively explore the emerging potential of nanotechnology-mediated drug delivery systems for targeted interventions in kidney diseases. We detail how the precise engineering of nanoparticle physicochemical properties and active targeting strategies enables targeted delivery to specific intrarenal sites and cell types, overcoming physiological barriers. Furthermore, we highlight promising preclinical advancements of nanotherapeutics designed to mitigate oxidative stress and inflammation in AKI, counteract pathological processes in various forms of CKD, and address inflammatory challenges in kidney transplantation. By integrating insights into the complex immunopathology of kidney disease with innovative nanotherapeutic strategies, this review underscores the significant potential for developing more effective, targeted, and personalized treatments to improve patient outcomes.

Indexed as

Acute Kidney InjuryKidney DiseasesNanomedicinePrecision MedicineRenal Insufficiency, ChronicDrug Delivery SystemsHumansInflammationKidneyNanoparticlesInflammationKidney repairNanoparticle-mediated drug delivery

Identifiers

PMID40900261
PMCPMC12935853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.